

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website : www.sunpharma.com
CIN : L24230GJ1993PLC019050



September 10, 2018

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
NSE Code – SUNPHARMA

BSE Ltd,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.
BSE Code– 524715

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


Dear Sirs,

This is to inform you that one of the wholly owned subsidiaries of the Company has agreed to acquire shares of Tarsius Pharma Ltd, (“Tarsius”), Israel, by way of subscription of 345,622 ordinary shares of nominal value of NIS 0.01 each, representing 18.75% of shares of Tarsius, on a fully diluted basis.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as per ‘Annexure A’.

This is for your information and record.

Yours faithfully,
For Sun Pharmaceutical Industries Limited,


Ashok I Bhuta
Compliance Officer



Enclosures:
1. Annexure A

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website : www.sunpharma.com
CIN : L24230GJ1993PLC019050

**Annexure A**

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as per 'Annexure A'.

a) Name of the target entity, details in brief such as size, turnover etc.;	i) Name of the Target: Tarsius Pharma Ltd. ("Tarsius") (Target) ii) Details of the Target: Tarsius is an Israel based early stage research and development company focusing on development of drug candidates in the field of Ophthalmology 2017 Sales: NIL
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length";	No, the acquisition would not fall within the related party transaction.
c) Industry to which the entity being acquired belongs;	Pharmaceuticals, Research and Development.
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Investment in Target entity by an indirect wholly owned subsidiary of Sun Pharmaceutical Industries Limited.
e) Brief details of any governmental or regulatory approvals required for the acquisition;	No governmental or regulatory approvals are required.
f) Indicative time period for completion of the acquisition;	Before 15 th September 2018
g) Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration towards subscription of shares of the Target entity.
h) Cost of acquisition or the price at which the shares are acquired;	Cost of acquisition is US\$ 3 million.



Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website : www.sunpharma.com
CIN : L24230GJ1993PLC019050



i) Percentage of shareholding / control acquired and / or number of shares acquired;	345,622 ordinary shares representing 18.75% of shares of the Target entity, on a fully diluted basis.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Brief background:</p> <p>Tarsius is an Israel based early stage research and development company focusing on development of drug candidates in the field of Ophthalmology.</p> <p>Date of incorporation: 21st February 2016</p> <p>Turnover of last 3 years: NIL</p> <p>Line of business: Early stage research and development of drug candidates in the field of Ophthalmology.</p> <p>Country in which the Target entity has presence: Israel</p>

